NOVALIQ Strengthens Executive Management Team with the Appointment of Gabriela Burian, MD, MPH, as Chief Medical Officer
NOVALIQ GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the appointment of Gabriela Burian, MD, MPH, as NOVALIQ’s Chief Medical Officer (CMO).
Dr. Burian brings over 25 years of international clinical experience to the company. She is responsible for leading NOVALIQ’s global clinical development and regulatory efforts, as well as expanding the company’s proprietary ocular therapeutics pipeline. Dr. Burian has deep clinical knowledge and proven leadership in the areas of ophthalmic biomedical research and clinical translation, with specialized expertise in retina diseases. Previously, Dr. Burian held various leadership positions, including Global Program Medical Director at Novartis Pharma and Ophthalmology Early Program Leader at F. Hoffmann-La Roche. She founded and directs GB Biomed Advisors GmbH and serves as CMO for Iconic Therapeutics, Inc. She is a faculty member of the European School for Advanced Studies in Ophthalmology.
“NOVALIQ has a very exciting and robust dry eye therapy pipeline and has the potential to address significant clinical needs in retina and glaucoma as well,” said Dr. Burian. “With multiple pre-clinical and clinical stage programs in development, the company is strongly positioned to be a global leader in dry eye disease. My top priorities are to advance these programs toward regulatory submissions and to identify, develop and manage new drug development opportunities in glaucoma and retina diseases by harnessing the power of NOVALIQ’s proprietary EyeSol® technology, which enhances the topical bioavailability, stability and safety of traditionally insoluble or unstable drugs.”
Sonja Krösser, PhD, vice president of preclinical and clinical development will continue to lead NOVALIQ’s dry eye developments and remains responsible for the preclinical and clinical team. Dr. Krösser is a translational science and clinical development expert with more than 15 years in the biopharmaceutic industry and in-depth experience in dry eye disease. She was and will be instrumental in the advancement of NOVALIQ’s rich and differentiated dry eye product pipeline, which includes the CE-approved NovaTears®; NovaTears® Omega-3 a new preservative-free, multi-dose eye drop formulation expecting CE mark in 2017; CyclASol®, currently in Phase 2 clinical trials in the U.S.; and, the recently announced, first-in-class ocular pain and anti-inflammatory cannabinoid DED drug development program.
Dr. Burian will join NOVALIQ’s executive management team, reporting to the company’s managing director and CEO Christian Roesky, PhD. “I’m delighted to welcome Gabriela to NOVALIQ ,” said Dr. Roesky. “With Gabriela’s extensive experience leading medical and clinical development teams combined with Sonja’s demonstrated track record of advancing our dry eye pipeline, we are strengthening our mission to transform active pharmaceutical ingredients (APIs) into highly effective ocular therapeutics for both the front and the back of the eye.”
About NOVALIQ– NOVALIQ GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. NOVALIQ’s proprietary EyeSol® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. NOVALIQ has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. NOVALIQ’s most advanced product is NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe. CyclASol® a second-generation prescription drug is currently in preparation for a pivotal trial. More on www.novaliq.com.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
GSMA Study: 5G to Account for a Third of Europe’s Mobile Market by 202517.10.2017 10:00 | Tiedote
More than 30 per cent of Europe’s mobile connections will be running on 5G networks by 2025, according to a new GSMA study. The 2017 Europe edition of the GSMA’s Mobile Economy series, published today at the GSMA Mobile 360 Series – Europe event in Brussels, forecasts that there will be 214 million 5G connections in Europe by 2025, establishing the region as one of the largest 5G markets in the world by that point. The first commercial 5G networks in Europe are due to be switched on by 2020 and are expected to provide 5G network coverage to almost three-quarters of Europe’s population by 2025. “Europe has an opportunity to reestablish itself as a global technology leader as we move toward the 5G era, but this can only happen if policymakers move quickly and boldly to make the necessary regulatory reforms to boost the region’s competitiveness on the global stage and bring innovative ser
REFLEX CES Partners with NOLAM EMBEDDED SYTEMS to Provide Integrated CANbus IP Core Solutions on FPGA COTS Boards17.10.2017 10:00 | Tiedote
NOLAM EMBEDDED SYSTEMS, manufacturer of semiconductor IP and board level products and systems for the Aerospace, Defense, telecom and industrial markets, today announced their partnership with REFLEX CES, a leading provider of complex, high-density FPGA-based boards. This partnership benefits customers by providing them a fully integrated solution based on REFLEX CES FPGA boards and NOLAM EMBEDDED SYSTEMS CANbus IP core and CANbus FMC module. «We are thrilled to collaborate with REFLEX CES to offer a fully integrated CANbus solution», stated Benjamin Nakache, Vice-President of Sales at Nolam Embedded Systems «By integrating our CANbus IP solution with our CANbus FMC to the REFLEX CES hardware, we bring a very easy-to use solution to CANbus users in the automotive industry.» One of the first outcomes of this collaborative venture is the release of an SDK, composed of REF
BNP Paribas Implements SmartStream’s TLM Fees and Expense Management Solution17.10.2017 10:00 | Tiedote
SmartStream, the Financial Transaction Lifecycle Management (TLM®) specialist, today announced that the Derivatives Execution & Clearing (DEC) business of BNP Paribas CIB has implemented its TLM Fees & Expense Management (FEMS) solution for two key objectives: To control and reconcile payable brokerage fees Invoice issuance to execute commissions for DEC clients FEMS will consolidate all fees which will be reconciled against invoices received. The solution will automate the invoice control process by managing the increase in volume growth and targeting essentially (1) the detection and resolution of disputes and (2) an acceleration of processing and payment turnaround time. Also, the solution will fully support the execution and commission billing process from DEC to its clients. Pierre Duret, Head of Clearing within BNP Pari
East and West Malaysia Gain Enhanced Mobile Broadband with SES Networks and CompuDyne17.10.2017 09:50 | Tiedote
CompuDyne, a leading telecommunications solutions provider in Malaysia, is partnering with SES Networks to bring high quality and cost-effective cellular backhaul service to both East and West Malaysia and its surrounding islands. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171016006356/en/ East and West Malaysia Gain Enhanced Mobile Broadband with SES Networks and CompuDyne (Photo: Business Wire) SES announced that CompuDyne has signed a multi-year, multi-transponder agreement to lease Ku-band capacity on SES-9, SES’s largest satellite dedicated to serve Asia-Pacific, for its customer Digi, the country’s leading mobile network operator. Making a shift from a C-band to Ku-band system, CompuDyne can now deliver more cost-effective and reliable satellite connectivity, enabling Digi
AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification17.10.2017 01:00 | Tiedote
AstraZeneca and its partner Chi-Med today presented preliminary safety and clinical activity of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib trials conducted in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with MET-amplification who had progressed following 1st-line treatment with an EGFR inhibitor.1,2 In both trials, the addition of savolitinib (600mg, once daily), an investigational selective inhibitor of c-MET (mesenchymal epithelial transition factor) receptor tyrosine kinase, to osimertinib (80mg, once daily) or gefitinib (250mg, once daily) demonstrated preliminary anti-tumour activity. The data were shared in two oral presentations at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan, 15-18 Oc
Orlando Melbourne Int’l (MLB) Lands Largest FAA Grant in Its History17.10.2017 00:34 | Tiedote
When Air Force One landed at Orlando Melbourne International Airport (MLB) in February, Airport Executive Director Greg Donovan took advantage of the opportunity and advised the president of the United States that his 747-200 just landed on a commercial runway officially rated ‘poor’ in aviation terms. That’s going to change, thanks to an $18,132,588 FAA grant announced by U.S. Secretary of Transportation Elaine Chao today. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171016006292/en/ Greg Donovan, A.A.E. (Photo: Business Wire) “We asked for, and received, tremendous support from the Florida congressional delegation,” said Jack L. Ryals, chairman of the Melbourne Airport Authority. “We are deeply grateful to Congressman Posey, Senator Nelson and Senator Rubio for their advocacy on this critic
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme